SCHEMBL4874262

SCHEMBL4874262

CC(C)c1ccc(CS(=O)(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47
IDO1 P14902 2/20 0.44
TYR P14679 2/20 0.41
RAB9A P51151 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CNR2 P34972 1/20 0.40
NLRP3 Q96P20 1/20 0.40
NPC1 O15118 2/20 0.39
PGR P06401 1/20 0.39
USP5 P45974 1/20 0.39
DRD3 P35462 2/20 0.39
KCNH2 Q12809 2/20 0.39
DRD2 P14416 1/20 0.39
F10 P00742 1/20 0.39
PRSS1 P07477 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5063575 0.91 BCHE (0.42) BCHEACHEIDO1TYRRAB9A
SCHEMBL15299023 0.84 CXCR1 (0.35) BCHEACHEKMT2A
SCHEMBL12858297 0.82 HDAC4 (0.45) RAB9AMEN1KMT2ANPC1
SCHEMBL8474031 0.82 CA2 (0.41) KMT2ASMN1; SMN2PRSS1PRSS2PRSS3
SCHEMBL20671867 0.81 ESR1 (0.39) BCHEACHE
SCHEMBL12089981 0.81 IDO1 (0.45) BCHEACHEIDO1TYRRXRA
SCHEMBL4739419 0.79 CA1 (0.54) BCHEACHEIDO1TYRMEN1
SCHEMBL21424164 0.79 IDO1 (0.44) BCHEACHEIDO1TYRRAB9A
SCHEMBL19106116 0.79 IDO1 (0.44) BCHEACHEIDO1TYRRAB9A
SCHEMBL16923057 0.77 L3MBTL1 (0.50) BCHEACHEIDO1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312208-A1 Pyridine Analogues ASTRAZENECA AB (SE) 2008-12-18 US disclosed
EP-1904474-A1 NEW PYRIDINE ANALOGUES AstraZeneca AB (SE) 2008-04-02 EP disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312208-A1 Pyridine Analogues P2RY12, P2RY11, P2RY1 BCHE 4609/4885ACHE 3874/4885IDO1 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.